EGFR-mutated NSCLC is a genetically heterogeneous disease that includes more than 200
distinct mutations. The implications of mutational subtype for both prognostic and predictive …

The clinical management of cancer has evolved in recent years towards more personalized
strategies that require a comprehensive knowledge of the complex molecular features …

PCR-based techniques routinely employed for the detection of mutated linear DNA
molecules, including circulating tumor DNA (ctDNA), require large nucleotide sections on …

Imaging and image-guided procedures play an imperative role in the screening, diagnosis,
and surveillance of cancer. Although emerging imaging techniques now enable more …

Cancer therapy agents have been used extensively as cytotoxic drugs against tissue or
organ of a specific type of cancer. With the better understanding of molecular mechanisms …

Circulating tumoral DNA (ctDNA), commonly named “liquid biopsy”, has emerged as a new
promising noninvasive tool to detect biomarker in several cancers including lung cancer …

In recent years, new therapeutic options have become available for prostate cancer (PC)
patients, generating an urgent need for better biomarkers to guide the choice of therapy and …

Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …

Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the
heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …

Cytokines are pivotal mediators of the immune response, and their coordinated expression
protects host tissue from excessive damage and oxidant stress. Nevertheless, the …